



**Leap Therapeutics, Inc.**  
47 Thorndike Street  
Suite B1-1  
Cambridge, MA 02141  
T: 617-341-7700  
F: 617-341-7701  
www.leaptx.com

October 14, 2020

**VIA EDGAR TRANSMISSION**

Securities and Exchange Commission  
Division of Corporation Finance  
100 F Street, N.E.  
Washington, D.C. 20549  
Attention: Jason L. Drory

**Re: Leap Therapeutics, Inc.  
Registration Statement on Form S-3  
Filed September 14, 2020, as amended  
File No. 333-248797**

Ladies and Gentlemen:

Pursuant to Rule 461 under the Securities Act of 1933, as amended, Leap Therapeutics, Inc. (the "Company") hereby requests acceleration of the effective date of its Registration Statement on Form S-3 (File No. 333-248797) (the "Registration Statement"), so that the Registration Statement may become effective at 4:00 p.m. (Washington, D.C. time) on October 16, 2020, or as soon as practicable thereafter.

LEAP THERAPEUTICS, INC.

By: /s/ Douglas E. Onsi  
Name: Douglas E. Onsi  
Title: Chief Executive Officer and President

---